share_log

Ladenburg Thalmann Initiates Coverage On Marker Therapeutics With Buy Rating, Announces Price Target of $11

Ladenburg Thalmann Initiates Coverage On Marker Therapeutics With Buy Rating, Announces Price Target of $11

拉登堡塔尔曼以买入评级开始对Marker Therapeutics进行报道,宣布目标股价为11美元
Benzinga ·  04/30 10:03

Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Marker Therapeutics (NASDAQ:MRKR) with a Buy rating and announces Price Target of $11.

拉登堡塔尔曼分析师艾登·侯赛诺夫开始对Marker Therapeutics(纳斯达克股票代码:MRKR)进行报道,评级为买入,并宣布目标股价为11美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发